Loss of renal medullary endothelin B receptor function during salt deprivation is regulated by angiotensin II.
We have recently demonstrated that chronic infusion of exogenous ANG II, which induces blood pressure elevation, attenuates renal medullary endothelin B (ET(B)) receptor function in rats. Moreover, this was associated with a reduction of ET(B) receptor expression in the renal inner medulla. The aim of this present work was to investigate the effect of a physiological increase in endogenous ANG II (low-salt diet) on the renal ET system, including ET(B) receptor function. We hypothesized that endogenous ANG II reduces renal medullary ET(B) receptor function during low-salt intake. Rats were placed on a low-salt diet (0.01-0.02% NaCl) for 2 wk to allow an increase in endogenous ANG II. In rats on normal-salt chow, the stimulation of renal medullary ET(B) receptor by ET(B) receptor agonist sarafotoxin 6c (S6c) causes an increase in water (3.6 ± 0.4 from baseline vs. 10.5 ± 1.3 μl/min following S6c infusion; P < 0.05) and sodium excretion (0.38 ± 0.06 vs. 1.23 ± 0.17 μmol/min; P < 0.05). The low-salt diet reduced the ET(B)-dependent diuresis (4.5 ± 0.5 vs. 6.1 ± 0.9 μl/min) and natriuresis (0.40 ± 0.11 vs. 0.46 ± 0.12 μmol/min) in response to acute intramedullary infusion of S6c. Chronic treatment with candesartan restored renal medullary ET(B) receptor function; urine flow was 7.1 ± 0.9 vs. 15.9 ± 1.7 μl/min (P < 0.05), and sodium excretion was 0.4 ± 0.1 vs. 1.1 ± 0.1 μmol/min (P < 0.05) before and after intramedullary S6c infusion, respectively. Receptor binding assays determined that the sodium-depleted diet resulted in a similar level of ET(B) receptor binding in renal inner medulla compared with rats on a normal-salt diet. Candesartan reduced renal inner medullary ET(B) receptor binding (1,414 ± 95 vs. 862 ± 50 fmol/mg; P < 0.05). We conclude that endogenous ANG II attenuates renal medullary ET(B) receptor function to conserve sodium during salt deprivation independently of receptor expression.
Section of Experimental Medicine, Department of Medicine, Georgia Health Sciences University, Augusta, GA 30912, USA.
Wararat
W
Kittikulsuth
Jennifer S
JS
Pollock
David M
DM
Pollock
D000804:Angiotensin II / Q000502:physiology*; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D001713:Biphenyl Compounds; D004039:Diet, Sodium-Restricted; D004231:Diuresis / Q000187:drug effects; D019332:Endothelin-1 / Q000378:metabolism; D019333:Endothelin-2 / Q000378:metabolism; D007679:Kidney Medulla / Q000378:metabolism*; D008297:Male; D009318:Natriuresis / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D044023:Receptor, Endothelin B / Q000819:agonists / Q000502:physiology*; D017673:Sodium Chloride, Dietary / Q000378:metabolism; D012982:Sodium, Dietary / Q000494:pharmacology; D013777:Tetrazoles / Q000494:pharmacology; D014757:Viper Venoms / Q000494:pharmacology
D001562:Benzimidazoles; D001713:Biphenyl Compounds; D019332:Endothelin-1; D019333:Endothelin-2; D044023:Receptor, Endothelin B; D017673:Sodium Chloride, Dietary; D012982:Sodium, Dietary; D013777:Tetrazoles; D014757:Viper Venoms; C057354:sarafotoxins s6; D000804:Angiotensin II; C081643:candesartan